Participant flow

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma · Source last updated 2026-02-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Subjects received at least one dose of study treatment

   id

   FG000

   title

   All Study Subjects

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Lack of Efficacy

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         39

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         14

      type

      NOT COMPLETED

   title

   Overall Study (Until End of Surgery)

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Progression

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   milestones

   1. achievements

      1. comment

         The participants were prescribed adjuvant chemotherapy based on the surgical pathology report included.

         group Id

         FG000

         num Subjects

         21

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         13

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         8

      type

      NOT COMPLETED

   title

   Adjuvant Chemotherapy

3. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Progression

   3. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Adverse Event

   milestones

   1. achievements

      1. comment

         The participants were prescribed adjuvant durvalumab based on the surgical pathology report included.

         group Id

         FG000

         num Subjects

         35

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      NOT COMPLETED

   title

   Adjuvant Durvalumab

4. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Progression

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   milestones

   1. achievements

      1. comment

         The participants were prescribed adjuvant radiotherapy based on the surgical pathology report included.

         group Id

         FG000

         num Subjects

         21

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         14

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      NOT COMPLETED

   title

   Adjuvant Radiotherapy

pre Assignment Details

A total of 44 participants consented, but 5 were deemed to be ineligible, and 39 subjects enrolled in the study; 37 out of 39 subjects completed neoadjuvant therapy, and 2 subjects were off the treatment due to toxicity; 35 out of 37 subjects underwent surgery at study centers, one subject had surgery elsewhere, and one subject declined the surgery. Subjects received adjuvant therapy based on surgical pathology results and treatment progress was submitted separately.

recruitment Details

Participants were recruited from 12/19/2017 through 11/09/2021 at 4 cancer centers in the United States.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice